Specify a stock or a cryptocurrency in the search bar to get a summary
Abcellera Biologics Inc
ABCLAbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company had discovery programs that are either completed, in progress, or under contract with partners. It has a research collaboration and license agreement with Eli Lilly and Company; and a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets. The company was incorporated in 2012 and is headquartered in Vancouver, Canada. Address: 2215 Yukon Street, Vancouver, BC, Canada, V5Y 0A1
Analytics
WallStreet Target Price
22 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures ABCL
Dividend Analytics ABCL
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History ABCL
Stock Valuation ABCL
Financials ABCL
Results | 2019 | Dynamics |